Optiver Holding
RAPP

Optiver Holding’s Rapport Therapeutics RAPP Stock Holding History

Optiver Holding’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.38K Buy
204
+132
+183% +$3.71K ﹤0.01% 1336
2025
Q4 		$2.18K Sell
72
-34
-32% -$941 ﹤0.01% 1969
2025
Q3 		$3.15K Buy
+106
New +$1.89K ﹤0.01% 2152

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Optiver Holding's RAPP Position: Q1 2026 in Review

Optiver Holding increased its Rapport Therapeutics (RAPP) stake by 183% in Q1 2026, buying an estimated $3.71K and bringing the position to 204 shares worth $6.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1336.

Optiver Holding first reported a position in RAPP in Q3 2025 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Optiver Holding held 204 shares of Rapport Therapeutics worth $6.38K as of Q1 2026.
  • Optiver Holding bought 132 Rapport Therapeutics shares in Q1 2026, an estimated $3.71K.
  • Rapport Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1336 holding.
  • Optiver Holding first reported a position in Rapport Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.